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Most studies on the sensitivities of coagulation assays to
direct oral anticoagulants (DOACs) are based on normal
plasma spiked with anticoagulant in the laboratory. Recent
studies have shown that reagent sensitivity varies signifi-
cantly depending on whether spiked or patient samples
are used. The aim of this study was to compare the sen-
sitivities of routine coagulation assays in patient samples
and commercial drug specific calibrators using commonly
used activated partial thromboplastin time (APTT) and
prothrombin time (PT) reagents (i.e., Actin FS and
Neoplastine CI Plus for APTT and PT, respectively) in
Australian laboratories. Samples collected at Pathology
North Hunter (PN-H) for dabigatran (n = 39), rivaroxaban,
(n = 56) or apixaban levels (n = 22) between February
2013 and November 2015 were analysed and compared to
two different commercial drug specific calibrators from
different manufacturers for each DOAC. Our results show
that dabigatran (Hyphen and Technoclone) and rivarox-
aban (Stago) calibrators tend to overestimate the APTT
but are similar to patient samples for PT. A cut-off DOAC
level of 50 ng/mL based on results from patient samples
within the laboratory can be used as the lower limit which
will result in prolongation of APTT for dabigatran (sensi-
tivity 96%, n = 25) and PT for rivaroxaban (sensitivity 97%,
n = 29), respectively. Individual laboratories should be
familiar with the sensitivity of their coagulation reagents to
different DOACs including differences between patient
samples versus different commercial drug specific
calibrators.
Key words: Direct oral anticoagulants; DOACs; activated partial thrombo-
plastin time; prothrombin time; patient samples; calibrators.
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Direct oral anticoagulants (DOACs) have the advantage of
more predictable pharmacokinetics and pharmacodynamics
compared to vitamin K antagonists such as warfarin and
therefore do not require routine laboratory monitoring.
However in some situations, such as bleeding, recurrent or3025/Online ISSN 1465-3931 © 2016 Royal College of P
er the CC BY license (http://creativecommons.org/licenses
i.org/10.1016/j.pathol.2016.07.008progressive thrombosis, emergency surgery, renal failure or
liver failure, laboratory monitoring may be required. This
includes baseline coagulation assays and functional antico-
agulant levels. Previous studies have shown that the sensi-
tivities of coagulation assays to the DOACs are reagent and
method dependent.1–7 Most of these early studies have been
based on spiked normal pooled plasma. Very few studies
were performed using patient samples.8–12 Regarding the use
of routine coagulation assays in the laboratory assessment of
DOACs, most guidelines recommend the use of activated
partial thromboplastin time (APTT) for dabigatran and pro-
thrombin time (PT) for rivaroxaban for urgent screening of
DOACs when the drug being assessed is known.13 Previous
guidelines such as the 2012 British Committee for Standards
in Haematology (BCSH) have suggested that a normal APTT
for dabigatran and PT for rivaroxaban excludes a therapeutic
intensity of the drug.14 This has been called into question by
several later studies performed using patient samples which
showed coagulation tests within the normal range even at
therapeutic levels of DOAC. In addition, the use of calibra-
tors (spiked samples) tended to overestimate the sensitivity of
routine coagulation tests to dabigatran and rivarox-
aban.10,15–19 In Australia, current guidelines by the Austral-
asian Society of Thrombosis and Haemostasis (ASTH)
recommend using speciﬁc quantitative assays, i.e., dilute
thrombin time and drug speciﬁc anti-factor Xa chromogenic
assay to assess dabigatran and rivaroxaban levels, respec-
tively.20 Since these assays may not be available in many
regional and remote laboratories and/or after hours, ASTH
recognises that routine coagulation assays such as thrombin
time (TT), APTT and PT can be utilised as screening tests to
provide qualitative information about the presence of
DOACs. However, caution should be given in adopting these
recommendations if commercial drug-speciﬁc calibrators are
used to determine the relative sensitivity of routine coagu-
lation to DOACs, as there are differences in spiked compared
to patient samples. Previous studies have comprehensively
evaluated the effect of DOACs on haemostasis tests in spiked
or patient samples but none have compared the sensitivity of
both the APTT and PT to different DOACs in patient samples
versus different drug-speciﬁc commercial calibrators.11,12,16
A recent study evaluated the use of a single drug-speciﬁc
commercial calibrator for determining PT or APTT reagent
sensitivity to dabigatran and rivaroxaban compared to patientathologists of Australasia. Published by Elsevier B.V. This is an open
/by/4.0/).
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commercial calibrators.18
Actin FS and Neoplastine CI Plus are the most common
APTT and PT reagents, respectively, used in Australian
laboratories, with a third of laboratories using these reagents.
In a survey of laboratories participating in the Royal College
of Pathologists of Australasia Quality Assurance Programs
(RCPA QAP) Haemostasis Program, Actin FS was the most
commonly used APTT reagent in 194 of 708 laboratories
(27%) among 15 other reagents. Neoplastine CI Plus was the
second most common PT reagent used after SM Thrombrel S
in 240 out of 730 laboratories (33%) among nine other PT
reagents.21
Our ﬁrst aim was to use a common APTT and PT reagent
in Australia (Actin FS and Neoplastine CI Plus, respectively)
to compare the sensitivities of routine coagulation assays to
DOACs in patient samples versus different commercial drug-
speciﬁc calibrators. If routine coagulation studies can be used
as a rough guide to determine whether signiﬁcant DOAC is
present, it would also be useful to know what approximate
level of DOAC would cause prolongation of the APTT or PT
using these reagents. The median trough level for dabigatran,
rivaroxaban and apixaban has been estimated to be around
90 ng/mL [95% conﬁdence interval (CI) 31–225], 32 ng/mL
[interquartile range (IQR) 19–60] and 63 ng/mL (95%CI
22–177), respectively.22–24 Corresponding median peak
levels were 184 ng/mL (95% CI 64–443), 244 ng/mL (IQR
175–360) and 132 ng/mL (95%CI 59–302), respectively.
Given the lower level sensitivity of the quantitating assays
(approximately 40 ng/mL for dilute thrombin time; 25 ng/mL
for chromogenic anti Xa assays),25–29 a level of 50 ng/mL
may be a reasonable target to suggest a limited haemostasis
related effect at that concentration/time point. Some studies
have reported so called ‘peak’ level ranges for some DOACs
of below 50 ng/mL,13,22,30,31 although it would be expected
that this will be a low occurrence rate, and potentially
representative of ‘non-compliance’ or maybe even ‘DOAC
resistance’ in occasional patients. Therefore, the second aim
of this study was to determine the distribution of samples
with routine coagulation assays above the normal range at a
speciﬁed cut-off drug level of 50 ng/mL using different
DOACs in patient samples.
MATERIALS AND METHODS
Patient samples
For this analysis, patient samples collected at Pathology North Hunter (PN-H)
between February 2012 and November 2015 requesting for dabigatran
(n = 65), rivaroxaban (n = 112), or apixaban levels (n = 31) were analysed
retrospectively. The data analysed consisted of results from coagulation
assays performed using Neoplastine CI Plus (Diagnostica Stago, France) and
Actin FS (Siemens, Germany) which are the primary reagents used in our
laboratory for PT and APTT testing, respectively. The testing was done by
mechanical clot detection method on a STA-R Evolution instrument (Diag-
nostica Stago). Dabigatran levels were tested by an in-house dilute thrombin
time akin to the commercially available Hemoclot assay from Hyphen
Biomed. Rivaroxaban and apixaban levels were performed using Liquid anti-
Xa chromogenic assay (STA liquid anti-Xa; Diagnostica Stago). Limits of
detection for dilute thrombin time and liquid anti-Xa chromogenic assays are
40 ng/mL26 and 25 ng/mL (package insert from manufacturer), respectively.
Levels below this were reported as ‘zero’. Patient samples where neither
APTT nor PT were requested (dabigatran n = 9; rivaroxaban n = 41; apixaban
n = 8) were excluded. Patient samples where only one of the PT or APTT
results were available which made up the minority were included in analysis
for the individual tests. Further samples were excluded if patients were onother oral anticoagulants (n = 3), had liver disease (n = 7), multiorgan failure
(n = 1) or if coagulation tests were abnormal when levels of DOACs were
undetectable (n = 18). After exclusions, the number of remaining samples
available for the ﬁnal analysis were dabigatran (n = 39), rivaroxaban (n = 56),
and apixaban (n = 22).
Commercial drug-speciﬁc calibrators
PT and APTT were performed on commercial drug-speciﬁc calibrators in
which DOAC levels were predetermined by the manufacturer using liquid
chromatography mass spectrometry (LC/MS-MS). Two calibrators sourced
from different manufacturers were used for each DOAC. For rivaroxaban and
apixaban, the calibrators were sourced from Diagnostica Stago (France) and
Technoclone (Austria), while for Dabigatran the calibrators were sourced
from Hyphen Biomed (France) and Technoclone (Austria).
Data analysis
Data were analysed using Microsoft Excel (Microsoft, USA). Linear regres-
sion lines and correlation coefﬁcient values, R2 were derived using the sta-
tistical software package included in Microsoft Excel. To compare the
sensitivity of APTT and PT in patient samples with commercial drug-speciﬁc
calibrators, APTT and PT were plotted against DOAC level in separate graphs
for each DOAC.
To further evaluate the differences between patient samples and commer-
cial drug-speciﬁc calibrators, we used difference plots (Bland–Altman plots)
obtained from the Analyse-it extension statistical software package for Excel.
For this analysis, a derived PT or APTT for the corresponding DOAC level in
patient samples was obtained from the drug-speciﬁc calibrator curve. The
difference or percentage difference between the derived APTT/PT from the
calibrator curve and the APTT/PT for patient samples was then plotted against
the mean APTT/PT (mean of APTT/PT from patient samples and derived
APTT/PT from calibrator curve). Mean and mean percentage differences were
indicated by the ‘plus’ sign if the derived clotting time was more prolonged
and ‘minus’ sign if the clotting time was shorter for commercial drug-speciﬁc
calibrators compared to patient samples. A two-tailed paired t test was used to
determine if the difference between mean APTT/PT for patient samples
compared with mean derived APTT/PT for commercial drug-speciﬁc cali-
brators were signiﬁcant (p < 0.05).
Ethics
This study was approved by Hunter New England (NSW) Human Research
Ethics Committee.
RESULTS
Sensitivity of APTT and PT to DOACs in patient
samples compared with commercial drug-speciﬁc
calibrators
The DOAC levels used for commercial drug-speciﬁc cali-
brators from various manufacturers and their corresponding
APTT/PT values are summarised in Table 1. Difference re-
sults from the Bland–Altman analysis comparing sensitivity
of APTT and PT to DOACs in patient samples versus drug-
speciﬁc commercial calibrators are shown in Table 2. For
DOAC levels in patient samples, a level below the limit of
detection in our laboratory as described in methods was re-
ported as ‘zero’.
Dabigatran
Dabigatran levels in patient samples ranged from 0 to 667 ng/
mL and the corresponding APTT and PT ranges were
28–104 s and 13–33 s, respectively. Correlation between
APTT clotting times and dabigatran levels in commercial
drug-speciﬁc calibrators (R2 = 1 for Hyphen and R2 = 0.9959
for Technoclone) was higher compared to patient samples
(R2 = 0.7717). Drug-speciﬁc calibrators overestimated the
sensitivity of the APTT to dabigatran compared to patient
Table 1 Summary of DOAC levels used for spiked samples using calibrators from various manufacturers and their corresponding APTT/PT values
Dabigatran Rivaroxaban Apixaban
Calibrator Level (ng/mL) APTT, s PT, s Calibrator Level (ng/mL) APTT, s PT, s Calibrator Level (ng/mL) APTT, s PT, s
Hyphen 30 49.9 17.0 Stago 0 33.1 13.4 Stago 0 29.8 14.2
255 84 23.8 98 42.8 19.2 90 31.5 15.3
468 106 36.2 241 52.9 26.5 228 32.9 16.8
495 66.4 36.6 455 36.2 19.6
Tech 0 33.1 14.1 Tech 0 30.1 14.1 Tech 0 32.3 13.8
65.2 48.1 15.7 48.3 35.0 15.5 64.4 34.3 14.3
212.7 64.7 19.3 101.3 41.9 19.8 215.9 36.1 16.0
408.6 84.4 24.4 199.2 48.1 23.9 433 37.7 17.5
514.8 93.2 29.3 433.3 55.4 34.3 623.5 39.7 19.1
APTT, activated partial thromboplastin time; Hyphen, Hyphen Biomed; PT, prothrombin time; s, seconds; Tech, Technoclone.
Table 2 Summary of Bland–Altman analysis
DOAC in spiked samples APTT bias (derived APTT from spiked sensitivity curve –
APTT patient samples)
PT bias (derived PT from spiked sensitivity curve –
PT patient samples)
Mean difference,
s (95%CI)
Mean percentage
difference, % (95%CI)
Mean difference,
s (95%CI)
Mean percentage
difference, % (95%CI)
Dabigatran
(Hyphen)
+16.4 (−2.9, 35.8)a +29.9 (0.3, 59.5)a +2.2 (−4.6, 9.0)a +10.4 (−13.7, 34.4)a
Dabigatran
(Technoclone)
+4.5 (−12.9, 21.9)a +9.3 (−21.3, 39.9)a −0.9 (−4.4, 2.6)a −4.8 (−25.1, 15.4)a
Rivaroxaban
(Stago)
+4.0 (−6.6, 14.6)a +10.2 (−18.3, 38.7)a −0.5 (−4.7, 3.6) NS −2.6 (−21.3, 16.2) NS
Rivaroxaban
(Technoclone)
+1.4 (−9.6, 12.4) NS +3.4 (−27.6, 34.4) NS −0.6 (−4.8, 3.6)b −3.0 (−22.0, 15.9)b
Apixaban
(Stago)
−0.5 (−8.3, 7.4) NS −0.5 (−24.2, 23.1) NS −1.0 (−3.8, 1.8)a −5.8 (−21.7, 10.1)a
Apixaban
(Technoclone)
+2.4 (−5.6, 10.5)b +8.4 (−24.6, 33.0)a −1.6 (−4.7, 1.5)a −9.9 (−27.0, 7.2)a
Shown are the activated partial thromboplastin time (APTT)/prothrombin time (PT) bias for each DOAC expressed as mean difference or mean percentage
difference. 95% conﬁdence intervals (CI) for mean difference or mean percentage difference are indicated in parentheses.
Corresponding p values for mean difference/mean percentage difference were obtained using a two-tailed paired t test: a p < 0.01; b p < 0.05; NS, not signiﬁcant, i.e.,
p > 0.05.
714 LIM et al. Pathology (2016), 48(7), Decembersamples (Fig. 1A). The mean difference in APTT was +16.4 s
(95%CI –2.9, 35.8 s) using Hyphen Biomed calibrators
and +4.5 s (95%CI –12.9, 21.9 s) using Technoclone cali-
brators by Bland–Altman analysis. Correlation between PT
clotting times and dabigatran levels in commercial drug-
speciﬁc calibrators (R2 = 1 for Hyphen and R2 = 0.9948 for
Technoclone) was also higher compared to patient samples
(R2 = 0.8457). Sensitivity of PT to dabigatran was similar in
patient samples and Technoclone calibrators with a mean
difference of –0.9 s (95%CI –4.4, 2.6 s) (Fig. 1B). At higher
concentrations of dabigatran, PT was increasingly more
sensitive in Hyphen Biomed calibrators compared to patient
samples with a mean difference +2.2 s (95%CI –4.6, 9.0 s).
Rivaroxaban
Rivaroxaban levels in patient samples ranged from 0 to
381 ng/mL. The corresponding APTT and PT ranges were
19–55 s and 14–38 s, respectively. There was better corre-
lation between APTT clotting times and rivaroxaban levels in
commercial drug-speciﬁc calibrators (R2 = 0.9993 for Stago
and R2 = 0.9963 for Technoclone) compared to patient
samples (R2 = 0.5397). Stago calibrators overestimated theAPTT compared to the patient samples with mean difference
of +4.0 s (95%CI –6.6, 14.6 s) whereas Technoclone cali-
brators had similar APTT sensitivity to patient samples,
i.e., +1.4 s (95%CI –9.6, 12.4 s) (Fig. 1C). Correlation be-
tween PT clotting times and commercial drug-speciﬁc com-
mercial calibrators (R2 = 0.9992 for Stago and R2 = 0.9930
for Technoclone) was higher compared to patient samples
(R2 = 0.8518). Sensitivity of PT to rivaroxaban was similar in
Stago and Technoclone calibrators compared to patient
samples with mean differences of –0.5 s (95%CI –4.7, 3.6 s)
and –0.6 s (95%CI –4.8, 3.6 s), respectively (Fig. 1D).
Apixaban
Apixaban levels in patient samples ranged from 0 to 283 ng/
mL. The corresponding APTT and PT ranges were 26–41 s
and 14–22 s, respectively. There was poor correlation be-
tween APTT clotting times and apixaban levels in patient
samples (R2 = 0.4811) but good correlation of APTT clotting
times with apixaban levels in commercial drug-speciﬁc cal-
ibrators (R2 = 0.9931 for Stago and R2 = 0.9601 for Tech-
noclone). Correlation between PT clotting times and
apixaban levels in commercial drug-speciﬁc calibrators
Paent samples = 0.1029x + 34.762
R² = 0.7717
Technoclone calibrators = -0.0001x2 + 0.1653x + 34.954
R² = 0.9948
Hyphen calibrators = -0.0001x2 + 0.183x + 44.51
R² = 1
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Fig. 1 Sensitivity of APTT Actin FS and PT Neoplastine CI Plus to DOACs in patient samples vs commercial drug-speciﬁc calibrators. (A) Dabigatran: APTT in patient
samples versus Technoclone or Hyphen Biomed calibrators. (B) Dabigatran: PT in patient samples versus Technoclone or Hyphen Biomed calibrators. (C) Rivaroxaban:
APTT in patient samples versus Stago or Technoclone calibrators. (D) Rivaroxaban: PT in patient samples versus Stago or Technoclone calibrators. (E) Apixaban: APTT
in patient samples versus Stago or Technoclone calibrators. (F) Apixaban: PT in patient samples versus Stago or Technoclone calibrators. Shown also are the equations
and correlation coefﬁcients (R2) for the line of best ﬁt. DOAC levels below the limits of detection (<40 ng/mL for dabigatran, <25 ng/mL for rivaroxaban and apixaban)
in our laboratory were reported as ‘zero’.
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716 LIM et al. Pathology (2016), 48(7), December(R2 = 0.9994 for Stago and R2 = 0.9956 for Technoclone)
was higher compared to patient samples (R2 = 0.6069). In
contrast to dabigatran and rivaroxaban, both APTT at higher
concentrations (Fig. 1E) and PT (Fig. 1F) appeared to be less
sensitive to apixaban in commercial drug-speciﬁc calibrators
compared to patient samples.Effect of DOACs on routine coagulation assays above
and below a speciﬁed cut-off drug level of >50 ng/mL
using Neoplastine CI Plus and Actin FS as reagents in
patient samples
APTT above and below a cut-off DOAC level of 50 ng/mL
The APTT was prolonged with dabigatran levels above 50
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30
40
50
60
70
80
90
100
110
)sceS(
TTPA
SF
nitcA
DOAC levels above or below
dabigatran <50ng/ml dabigatra
rivaroxaban >50ng/ml apixaban
n= 24
n= 1
n =4
n= 2
10
15
20
25
30
35
)sceS(
TPsulpIC
enitisalpoe
N
DOAC levels above or below 5
dabigatran <50ng/ml dabigatr
rivaroxaban >50ng/ml apixaban
n= 0
n= 14
n= 21
n= 2
n= 6
n= 21
Dabigatran Rivarox
A
B
Dabigatran Rivarox
n= 0
n= 13
Fig. 2 Distribution of samples with prolonged coagulation tests above and below a c
the normal range for the speciﬁc coagulation assay, i.e., 24–36 s for APTT and 12–
APTT or PT.samples apart from one sample which had an APTT at the
upper limit of normal range, i.e., 36 s [APTT reference range
(RR) 24–36 s] with a dabigatran level of 72 ng/mL. APTT
was not prolonged in seven of 22 samples at rivaroxaban
levels above 50 ng/mL (median 135 ng/mL, IQR 89–220 ng/
mL). Seven of 10 samples were within the normal range for
APTT at apixaban levels of above 50 ng/mL (median 132 ng/
mL, IQR 87–179 ng/mL) (Fig. 2A).
PT above and below a cut-off DOAC level of 50 ng/mL
PT was sensitive to dabigatran at levels above 50 ng/mL
(median 169 ng/mL, IQR 104–243 ng/mL) for all but two
samples, which yielded results within the normal range (i.e.,
PT 13 s at dabigatran level 148 and PT 16 s at dabigatran
level 114). For rivaroxaban, the PT was sensitive to 50ng/ml in paƟent samples 
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96–231 ng/mL). Only one of 29 samples did not have a
prolonged PT (PT 16 s, RR 12–16 s) at rivaroxaban level
98 ng/mL. Apixaban was not sensitive to PT at levels above
50 ng/mL (median 141 ng/mL, IQR 98–153 ng/mL) with
seven of 13 samples within the normal range (Fig. 2B).
DISCUSSION
Differences between patient and commercial drug-
speciﬁc calibrators
Commercial drug-speciﬁc calibrators and patient samples
differ in several ways. Spiked normal pooled plasma is
readily available from various manufacturers as commercial
calibrators for coagulation assays and these are preferred in
laboratory quality control programs as well as research
studies. In contrast, patient samples requires recruitment of
individual donors which is challenging and time consuming.
Commercial calibrators are usually lyophilised (freeze dried)
prior to storage and have to be reconstituted. Studies have
shown that clotting factor activities in lyophilised plasma
remain stable after 24 months of storage at room temperature
and up to 6 days after reconstitution when stored at 4C.32,33
Based on these studies, loss of clotting factor activities due to
prolonged storage and reconstitution in lyophilised plasma
would not be anticipated to have a signiﬁcant effect on
routine coagulation assays. However, there are some studies
that have shown that the use of lyophilised plasma may
prolong PT and APTT values compared to fresh plasma.34,35
This suggests that these differences may be due to intrinsic
differences in factor concentrations at source which may vary
depending on the manufacturer or lot number of the particular
plasma used. As drug-speciﬁc commercial calibrators used to
quantitate DOAC levels are only designed to measure the
drug level, the ‘normality’ of the plasma spiked with the
DOAC is not usually considered important by the manufac-
turer as each DOAC assay is designed to be insensitive to any
coexisting factor deﬁciencies. Thus spiked ‘normal’ pooled
plasma used in commercial drug-speciﬁc calibrators in fact
may be variable in regards to concentration of some clotting
factors. In keeping with this, only drug levels, and not the
factor levels, in commercial drug-speciﬁc calibrators used for
coagulation assays are routinely checked prior to release by
some manufacturers (personal correspondence via email).Sensitivity of routine coagulation assays to DOACs in
patient samples versus commercial drug-speciﬁc
calibrators
Previous studies have shown that the APTT is more sensitive
to dabigatran and rivaroxaban in patient samples compared
with spiked samples.4 To our knowledge, this is the ﬁrst
study to compare the sensitivity of both APTT and PT to
different DOACs in patient samples versus different drug-
speciﬁc commercial calibrators. Our study shows that dif-
ferences in sensitivity of the coagulation assays in patient
samples compared to drug-speciﬁc commercial calibrators
vary depending on (1) type of coagulation assay, (2) DOAC
used, and (3) the commercial drug-speciﬁc calibrator used to
establish the spiked DOAC sensitivity curves. Reasons for
the differences in sensitivity to DOACs in calibrator material
compared to patient samples are unclear, although one study
suggested that this may be due to antibiotic used as apreservative in calibrator material affecting some PT and
APTT reagents.18 Recommendations on the use of PT and
APTT alone as an indicator of DOAC levels based on com-
mercial drug-speciﬁc calibrators therefore should be inter-
preted with caution as routine coagulation assays are based on
patient samples. For example, a normal APTT in patient
samples for dabigatran and rivaroxaban may correspond to a
higher level of DOAC than suggested by studies based on
drug-speciﬁc commercial calibrators as the APTT is less
sensitive in patient samples. However, whether these differ-
ences translate clinically into signiﬁcant differences in
bleeding is unknown.
Using cut-offs to estimate DOAC levels based on routine
coagulation tests in patient samples
Using Actin FS and Neoplastine CI Plus as reagents in pa-
tient samples, a speciﬁed cut-off drug concentration of
50 ng/mL could be used as an estimate of the lower limit
above which the APTT for dabigatran and the PT for
rivaroxaban would be prolonged in most samples. To our
knowledge, our study is the ﬁrst to report this. This was not
the case for apixaban which had no effect on the APTT and
PT, even at concentrations exceeding 100 ng/mL. In gen-
eral, a DOAC concentration of <50 ng/mL would suggest a
limited haemostasis related effect at that concentration/time
point. Thus a normal APTT for dabigatran and PT for
rivaroxaban can be used as a rough guide as to whether
signiﬁcant drug is present using a sensitive reagent such as
Actin FS for APTT and Neoplastine CI Plus for PT. This
would be especially useful for laboratories where routine or
after hours drug levels are not available. However for ac-
curate estimation, the dilute thrombin time for dabigatran
and drug speciﬁc anti-factor Xa assay for rivaroxaban and
apixaban should still be used.14,20,36–38 Indeed, most recent
guidelines accept that a normal PT and APTT will not
exclude possible rivaroxaban and dabigatran ‘within therapy
range’, although this will be true for most samples giving
normal PT and APTT.15,39–41 It is also important to
emphasise that these results may vary if a different reagent/
instrument combination is used.15 Hence each laboratory
should be aware of the sensitivity of their coagulation assays
to the DOACs.
Comparison and correlation of this study with
previously published studies
The British Committee for Standards in Haematology
(BCSH), as well as the Subcommittee on Control of Anti-
coagulation of the Scientiﬁc and Standardization Committee
of the International Society on Thrombosis and Haemostasis
(ISTH) state that the APTT and PT can be used to determine
the relative intensity of anticoagulation caused by dabigatran
and rivaroxaban respectively if drug speciﬁc quantitative
assays are not available.14,36 In addition, the 2012 BCSH
guidelines propose that that a normal APTT for dabigatran
and PT for rivaroxaban excludes a therapeutic intensity of the
drug.14 These international recommendations suggest that
each laboratory should be aware of the sensitivity of their
own PT and APTT assays to dabigatran and rivaroxaban
which can be achieved using commercially available dabi-
gatran and rivaroxaban calibrators. A recently published
study by Gosselin et al.18 compared the use of a single drug-
718 LIM et al. Pathology (2016), 48(7), Decemberspeciﬁc commercial calibrator to patient samples for deter-
mining PT or APTT reagent sensitivity to dabigatran and
rivaroxaban. They demonstrated signiﬁcant differences and
cautioned against the use of drug-speciﬁc calibrators to
determine the effect of DOACs on routine coagulation tests
and other specialised haemostasis assays (e.g., factor levels
and protein S). They also compared the sensitivity of three
different APTT and PT reagents to dabigatran and rivarox-
aban using Hyphen Biomed calibrators and patient samples.
APTT reagents used, i.e., SynthASil, Actin FSL, and PTT-A
were different from the APTT reagent used in our study
(Actin FS). Of the three PT reagents used, i.e., Recombi-
plastin 2G, Innovin, and Neoplastine CI plus, one was similar
to that used in our study (Neoplastine CI plus). Relative
sensitivities were compared using drug concentration
required to double the clotting time (2CT) from baseline of
the normal pooled plasma (NPP) sample as opposed to the
Bland–Altman method that we used in our study. It was
shown that Hyphen calibrators overestimated APTT or PT
sensitivity to dabigatran compared to patient samples using
Actin FSL and all three PT reagents. In our study using Actin
FS as APTT reagent, both Hyphen and Technoclone cali-
brators also overestimated APTT sensitivity to dabigatran
compared to patient samples. Using Neoplastine CI Plus as
PT reagent, Hyphen calibrators overestimated the sensitivity
of the PT to dabigatran similar to the above study but
Technoclone calibrators underestimated the PT (Table 2).
This suggests that the relative sensitivity of routine coagu-
lation assays to dabigatran in drug-speciﬁc calibrators
compared with patient samples are both reagent and cali-
brator speciﬁc. With regards to rivaroxaban, Gosselin et al.18
demonstrated that Hyphen calibrators overestimated the
sensitivity of all APTT and PT reagents used in their study
compared to patient samples including the PT reagent
Neoplastine CI Plus as used in our study. In our study,
different calibrators (Stago and Technoclone) were used but
using the same PT reagent (Neoplastine CI Plus) the sensi-
tivity of PT to rivaroxaban in Stago and Technoclone cali-
brators were similar to patient samples. The reasons for
differences in the relative sensitivities of APTT and PT to
dabigatran and rivaroxaban in drug-speciﬁc calibrators
compared with patient samples using different reagent-
calibrator combinations observed in our study and the study
by Gosselin et al. are unclear. However, it should be noted
that different methods were used for comparing relative
sensitivities. It is also interesting to note that using one
calibrator and reagent combination similar in both studies,
i.e., Hyphen and Neoplastine CI Plus, the relationship be-
tween dabigatran levels and PT in our study (curvilinear) was
different compared to that obtained by Gosselin et al.
(linear).18Study limitations
Limitations of our study include the limited number of
reagents and commercial drug-speciﬁc calibrators used.
Future studies comparing the sensitivity of routine coagu-
lation assays in patient samples versus commercial drug-
speciﬁc calibrators using different reagent and commer-
cial drug-speciﬁc calibrator combinations would be infor-
mative. In addition, being a retrospective study, a number
of samples (n = 26 dabigatran, n = 56 rivaroxaban andn = 9 apixaban) had to be excluded because of missing
information.
CONCLUSION
Each laboratory has to be familiar with the sensitivity of their
coagulation assays to different DOACs including differences
in patient samples compared to different commercial drug-
speciﬁc calibrators. Using a sensitive reagent, a cut-off
DOAC level based on patient samples which will result in
prolongation of APTT for dabigatran and PT for rivaroxaban
can be established in individual laboratories and used as a
rough guide for whether signiﬁcant DOAC is present when
speciﬁc assays for DOAC levels are not available.
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